473A.STU Adaptimmune Therapeutics PLC
- Market cap
- -
- P/E
- -
- P/B
- 2.63x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2025.
Is 473A.STU undervalued?
Graham numberThe Graham number of Adaptimmune Therapeutics PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adaptimmune Therapeutics PLC fundamental analysis
No fundamental analysis for Adaptimmune Therapeutics PLC yet.
Adaptimmune Therapeutics PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
Adaptimmune Therapeutics PLC financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Adaptimmune Therapeutics PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 59.5M | 2.23M | 3.96M | 6.15M | 27.1M | 60.3M | 178M | 41.9M |
| Gross Profit | - | - | - | - | 27.1M | 60.3M | 178M | 35.2M |
| Operating Income | -82.4M | -130M | -133M | -162M | -164M | -138M | -52.4M | -148M |
| EBITDA | -74.6M | -132M | -126M | -156M | -157M | -103M | -52.7M | -138M |
| Net Income | -95.5M | -127M | -130M | -158M | -165M | -114M | -70.8M | -156M |
| EPS | -0.15 | -0.20 | -0.14 | -0.17 | -0.17 | -0.08 | -0.05 | -0.10 |
| Balance Sheet | ||||||||
| Total Assets | 277M | 182M | 451M | 470M | 329M | 283M | 246M | 131M |
| Total Liabilities | 29.9M | 57.9M | 110M | 264M | 247M | 243M | 234M | 202M |
| Shareholders' Equity | 247M | 124M | 341M | 206M | 81.9M | 39.5M | 11.8M | -71.0M |
| Cash & Short-term Investments | 68.4M | 50.4M | 56.9M | 150M | 108M | 144M | 91.1M | 26.1M |
| Cash Flow | ||||||||
| Operating Cash Flow | -104M | -50.2M | -53.6M | 10.7M | -142M | -141M | -73.2M | -203M |
| Capital Expenditure | 4.71M | 1.82M | 2.91M | 8.78M | 29.7M | 4.88M | 2.72M | 2.56M |
| Free Cash Flow | -109M | -52.0M | -56.5M | 1.95M | -172M | -146M | -75.9M | -205M |
| Ratios | ||||||||
| ROE | -38.7% | -102.5% | -38.1% | -76.8% | -202.1% | -288.2% | -597.6% | - |
| ROA | -34.5% | -69.8% | -28.8% | -33.7% | -50.3% | -40.3% | -28.8% | -119.3% |
| Net Profit Margin | -160.5% | -5,687.3% | -3,286.8% | -2,571.0% | -609.5% | -188.9% | -39.8% | -371.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Adaptimmune Therapeutics PLC dividends
Adaptimmune Therapeutics PLC has not paid dividends in the last 7 fiscal years.
Who owns Adaptimmune Therapeutics PLC
Ownership data of Adaptimmune Therapeutics PLC is not available yet.
Adaptimmune Therapeutics PLC company profile
- Company name
- Adaptimmune Therapeutics PLC
- Ticker
- 473A.STU
- Exchange
- Stuttgart Exchange
- Sector
- -
- Industry
- -
- Fiscal year end
- December
- Address
- Website
- -